Meningococcal Immunization Against Gonococcal Infection (MAGI) Trial/ RV564

Closed Pre-Solicitation Posted

Not the latest version. See the latest special notice from .

Solicitation number
W81XWH-22-R-0810
Agency
Responses due
Set-aside
No set-aside

Opportunity facts

Place of performance
United States

Notice details come from SAM.gov. Updated .

About this opportunity

This pre-solicitation notice seeks capabilities to support the Meningococcal Immunization Against Gonococcal Infection Trial being conducted by the Infectious Diseases Clinical Research Program within the Department of the Army Medical Command. The trial aims to assess the efficacy of the Bexsero meningococcal vaccine in preventing gonococcal infection. Respondents should describe their ability to provide program management, data collection and analysis, sample collection and storage, and reporting. The response deadline is August 16th, 2022. Evaluation criteria will include the respondent's technical approach and past performance.

There is no set-aside designated for this requirement. Potential incumbents with relevant experience include the Infectious Diseases Clinical Research Program, Uniformed Services University, Walter Reed National Military Medical Center, and the National Institute of Allergy and Infectious Diseases. The trial timeline and key numerical details such as the number of subjects or samples involved are not specified in the pre-solicitation notice.

Notice text

Subject: Meningococcal Immunization Against Gonococcal Infection (MAGI) Trial/ RV564

Files

File Type Posted
B01-RFI Sources Sought_10AUG2022.pdf PDF

Notice history

Notice Type Posted
Meningococcal Immunization Against Gonococcal Infection (MAGI) Trial/ RV564 Latest special notice Special Notice
This notice Original Pre-Solicitation

On GovTribe

Work this opportunity

  • Track it in your pipeline
  • Find teaming partners
  • Similar opportunities
  • Ask GovTribe AI about this opportunity

GovTribe for Federal Contractors